Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment

Ionis Pharmaceuticals announced FDA approval of ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare progressive neurological disorder driven by GFAP pathogenic variants. The regulatory milestone supports a potentially differentiated commercial profile for IONS. The approval is a major positive catalyst for sentiment around the asset and company.